36results about How to "High practical value for clinical diagnosis" patented technology

The invention belongs to the field of analytic chemistry and clinical medicine and discloses a fetal macrosomia auxiliary diagnostic marker and application thereof. The marker is the combination of nicotinamide and citric acid and can be used for manufacturing a fetal macrosomia diagnosing or monitoring kit. The marker has the better auxiliary diagnostic effect on fetal macrosomia, can lower the detection cost and reduce economical burdens of a patient and is beneficial to clinical usage and popularization.

The invention belongs to the field of analytical chemistry and clinical medicine and discloses an idiopathic male infertility-related medium-chain fatty acid marker in serum and a detection method and application thereof. The marker is capric acid and/or lauric acid, and an UPLC-Q exactive MS method is adopted for detection. The marker can be used for auxiliary diagnosis and monitoring of idiopathic male infertility, has high sensitivity and specificity, and has clinic promotion value.

The invention belongs to the fields of analytical chemistry and clinical medicine, and discloses an idiopathic male infertility-related seminal plasma metabolic small molecular marker as well as a detection method and application thereof. The marker is prepared from seminal plasma metabolic small molecular acetylcarnitine and/or tryptophan, and is detected by adopting a UPLC-Q exactive MS method; the marker can be used for auxiliary diagnosis and monitoring of the idiopathic male infertility, and has higher sensitivity and specificity, thus having a clinical popularization value.

Belonging to the field of analytical chemistry and clinical medicine, the invention discloses an idiopathic male infertility related steroid hormone marker in serum, a detection method and application thereof. The marker is cortisol and/or dehydroepiandrosterone, a UPLC-Q exactive MS method is employed for detection, the marker can be used for auxiliary diagnosis and monitoring of idiopathic male infertility, has high sensitivity and specificity, and has clinical promotion value.

The invention belongs to the field of analytic chemistry and clinical medicine, and discloses a metabolism marker related to idiopathic male infertility in urine, and a detection method and application thereof. The metabolism marker is L-leucine and/or L-palmitoyl carnitine, is detected by adopting UPLC-Qexactive MS method, can be used for auxiliary diagnosis and monitoring of idiopathic male infertility, has higher sensitivity and specificity, and has a clinical spread value.

The invention belongs to the field of analytical chemistry and clinical medicine and discloses the urine estrogen metabolite markers related to idiopathic male infertility and the detection methods and application. The marker is the urine estrogen metabolite 2-methoxyestradiol and/or androstenedione and detected by UPLC Q exactive MS method. The urine estrogen metabolite markers related to idiopathic male infertility can be used for auxiliary diagnosis and monitoring of idiopathic male infertility, and has high sensitivity, specificity, and clinical spread value.

The invention belongs to the field of analytical chemistry and clinical medicine, and discloses an application of lead and cadmium mixing exposure detection in an assistant diagnosis of azoospermia. An exposed biomarker associated with the azoospermia is the mixing exposure of the lead and the cadmium. The concentration of the lead and the cadmium in whole blood can be detected by ICP-MS (Inductively Coupled Plasma Mass Spectrometry), which can be used for the assistant diagnosis of the azoospermia. The application of the lead and the cadmium mixing exposure detection in the assistant diagnosis of the azoospermia has the advantages of less blood volume, simple operation, fast, accurate, and good clinical promotion value.

The invention belongs to the field of analytical chemistry and clinical medicine, and discloses application of mercury and cadmium mixed exposure detection in auxiliary diagnosis of non-obstructive azoospermia. An exposed biomarker related to the non-obstructive azoospermia is mercury and cadmium mixed exposure. The concentration of mercury and cadmium in whole blood is detected by ICP-MS detection, the application can be used for auxiliary diagnosis of the non-obstructive azoospermia, a few amount of blood is used, and the application is simple, rapid and accurate to operate and has relatively good clinical promotion value.

The invention belongs to the field of analytical chemistry and clinical medicine and discloses idiopathic male infertility diagnostic markers serine and sorbitol in seminal plasma as well as a detection method and application thereof. The markers are serine and/or sorbitol and are detected by adopting a UPLC (Ultrahigh Performance Liquid Chromatography)-Qexactive MS (Mass Spectrum) method; and the markers can be used for auxiliary diagnosis and monitoring of idiopathic male infertility, have relatively high sensitivity and specificity and have a clinical popularization value.

The invention belongs to the field of analytical chemistry and clinical medicine, and provides UPLC-Q exactive MS detection of mannose-6-phosphoric acid and neopterin related to idiopathic male sterility in seminal plasma and application thereof. According to the invention, the UPLC-Q exactive MS is adopted to compare metabolic small molecules in normal control and idiopathic male sterility seminal plasma, and the fact that the seminal plasma contains a combination of mannose-6-phosphoric acid and neopterin which can be used for evaluating whether a patient suffers from idiopathic male sterility and has diagnostic value is found, and the application of the UPLC-Q exactive MS for detecting mannose-6-phosphoric acid and neopterin is found, so that an idiopathic male sterility diagnosis and monitoring kit which can be conveniently applied clinically is developed.

The invention belongs to the fields of analytical chemistry and clinical medicine and discloses a detecting method of a lead-cadmium mixed-exposure marker related to sex-hormone abnormality and an application thereof. The lead-cadmium mixed-exposure marker related to sex-hormone abnormality is the lead-cadmium mixed-exposure marker. The detecting method adopts ICP-MS to detect the concentration oflead and cadmium in whole blood, can be used for auxiliary diagnosis on the sex-hormone abnormality, is less in blood use amount, is simple, fast and accurate in operation and has better clinical promotion value.

The invention belongs to the fields of analytical chemistry and clinical medicine, and discloses gluconolactone and pyroglutamic acid as a macrosomia auxiliary diagnostic marker and application thereof. The marker is serum metabolic small molecule gluconolactone and pyroglutamic acid during pregnancy. The marker is detected by a UPLC-Q exactive MS method, and has good sensitivity and specificity.The marker can be used for early diagnosis or monitoring of macrosomia, and has relatively good clinical application and promotion value.

The invention belongs to the field of analytical chemistry and clinical medicine, and discloses a diagnostic marker of idiopathic male infertility by detecting deoxycytidine and cytidine in seminal plasma and an application thereof. The marker is deoxycytidine and/or cytidine, has high sensitivity and specificity in the diagnosis of the idiopathic male infertility, and can be used for preparing adiagnosis or monitoring reagent for idiopathic male infertility.

The invention belongs to the fields of analytical chemistry and clinical medicine, and discloses detection of arsenic and cadmium mixed exposure as a low birth weight auxiliary diagnosis marker basedon ICP-MS (inductively coupled plasma-mass spectrometry) and application of the marker. The low birth weight related exposure biomarker is the arsenic and cadmium mixed exposure. Arsenic and cadmium concentrations in whole blood are detected by adopting the ICP-MS, and the marker can be used for auxiliary diagnosis of low birth weight; the use amount of the blood is small; the operation is simple,quick and accurate; and the clinical popularization value is relatively good.

The invention belongs to the field of the analytical chemistry and the clinical medicine, and discloses a method for taking tryptosol and xanthosine in urine as idiopathic male infertility diagnosis markers and an application of the method. The markers are tryptosol and xanthosine which have relatively high sensitivity and specificity in the diagnosis of the idiopathic male infertility, and can beused for preparing the reagent for idiopathic male infertility diagnosis or monitoring.

The invention relates to a molecular marker related to azoospermia and a detection method and application thereof, and belongs to the technical field of analytical chemistry and clinical medicine. Metabolic small molecules in normal control and azoospermia semen are compared by adopting UPLC-Qexactive MS (Ultra Performance Liquid Chromatography-Quantitative Active Mass Spectrometry), 1, 3-dihydroxypropyl-2-yl pentadecanoate which can be used for evaluating whether the semen suffers from azoospermia or not and has diagnostic value exists in the semen, and the application of the UPLC-Qexactive MS for detecting the 1, 3-dihydroxypropyl-2-yl pentadecanoate is found, so that the 1, 3-dihydroxypropyl-2-yl pentadecanoate can be used for evaluating whether the semen suffers from azoospermia. And the azoospermia diagnosis and monitoring kit convenient for clinical application is developed. Metabolic small molecules are novel biomarkers, are highly associated with disease outcomes, and are stable, non-invasive, easy to detect and accurate in quantification. The 1, 3-dihydroxypropyl-2-yl pentadecanoate provided by the invention can be used as a diagnostic marker of azoospermia, provides a basis for further deep examination of clinicians, provides support for quickly and accurately mastering the disease state and the severity of the disease state of a patient and timely taking a prevention and treatment scheme, and delays and prevents disease progression.

The invention belongs to the field of analytical chemistry and clinical medicine, and discloses a 1-palmitoyl-SN-glycerin-phosphorylcholine and dodecanedioic acid as idiopathic male infertility diagnostic marker and application thereof. The marker is urine 1-palmitoyl-SN-glycerin-phosphorylcholine and dodecanedioic acid, has relatively high sensitivity and specificity in diagnosis of male infertility, and can be used for preparing idiopathic male infertility diagnosis or monitoring reagent.

The invention relates to a molecular marker related to azoospermia in semen as well as a detection method and application of the molecular marker, and belongs to the technical field of analytical chemistry and clinical medicine. Metabolic small molecules in normal control and azoospermia seminal fluid are compared by adopting UPLC-Qexactive MS (Ultra Performance Liquid Chromatography-Quantitative Exactive MS), 1, 3-dihydroxypropyl-2-yl 13-methylmyristic acid which can be used for evaluating whether the seminal fluid suffers from azoospermia or not and has a diagnostic value is found to exist in the seminal fluid, and the application of the UPLC-Qexactive MS for detecting the 1, 3-dihydroxypropyl-2-yl 13-methylmyristic acid is found to be used for evaluating whether the seminal fluid suffers from azoospermia or not. And the azoospermia diagnosis and monitoring kit convenient for clinical application is developed. Metabolic small molecules are novel biomarkers, are highly associated with disease outcomes, and are stable, non-invasive, easy to detect and accurate in quantification. The 1, 3-dihydroxypropyl-2-yl 13-methylmyristic acid provided by the invention can be used as a diagnostic marker of azoospermia, provides a basis for further examination of clinicians, provides support for quickly and accurately mastering disease states of patients and timely taking prevention and treatment schemes, and delays and prevents disease progression.

The invention belongs to the field of analytical chemistry and clinical medicine, and is particularly relates to a detection method based on GC-MS (gas chromatography-mass spectrometry) sperm countingand application; the detection method comprise the steps: stage one, selecting research objects and providing grouping basis; stage two, preparing a sample; stage three, loading the sample; and stagefour, carrying out data analysis. The objects of the invention are to: establish the GC-MS based detection method for pendimethalin exposure in serum; apply pendimethalin exposure as an effect markerof sperm count reduction; and develop a diagnostic kit for pendimethalin exposure detection in serum. The detection of pendimethalin exposure in serum provided by the invention helps predict the riskof reduced sperm count in an early stage through a minimally invasive mode; compared with semen collection, the pendimethalin exposure detection is more time-saving and handier, is suitable for earlyscreening for the sperm count of a male of childbearing age, and can provide basis for further in-depth examination for clinicians.